Oura’s Ambitious Move Toward an IPO
Oura, a Finnish company renowned for its ring-shaped health tracker worn by millions around the world, has taken a significant step toward going public. According to recent reports, the company has confidentially submitted draft paperwork to the US Securities and Exchange Commission (SEC) for a proposed initial public offering (IPO). While details such as the number of shares and expected price range remain undisclosed, the company’s financial trajectory is impressive.
In the fall of 2025, Oura secured a funding round that valued the business at approximately $11 billion (€9.5bn), more than doubling its valuation from a previous round in 2024, which stood at $5 billion (€4.3bn). This rapid growth highlights the company’s strong market position and investor confidence.
CEO Tom Hale shared that over 5.5 million Oura rings had been sold by the end of the third quarter of last year. He also projected that the company would achieve $2 billion (€1.7bn) in annual revenue in 2026, a significant jump from the $500 million (€430mn) it generated just two years prior. This projection underscores the company’s ambitious growth strategy and its expanding market reach.
The move toward an IPO places a European wearable brand on Wall Street’s radar at a time when investor interest in consumer health technology appears to be rebounding. Oura has emerged as a standout name in the fast-growing smart ring category, competing against industry giants like Apple, Garmin, and Samsung. Its distinct hardware design appeals to consumers who find traditional smartwatches more obtrusive.
Expansion into Software, Subscriptions, and AI
Over the past two years, Oura has aggressively expanded into software, subscriptions, and AI-powered health analysis. Its wearable platform now focuses on long-term health signals, including sleep, readiness, heart rate, stress, and recovery. This shift reflects a broader trend in the health tech industry, where companies are moving beyond hardware to offer comprehensive digital solutions.
More recently, Oura has pushed further into women’s health and AI-based personal coaching. It has developed tools designed to interpret physiological data and provide tailored wellness recommendations. Analysts view this transition from a device maker to a subscription-based health platform as central to its IPO pitch. The company is currently on pace to surpass 5 million paid members, highlighting its growing user base and potential for sustained revenue.
A European Tech Champion Heading to US Markets
The IPO filing marks a significant moment for one of Europe’s most prominent health tech success stories. Founded in Finland and developed around research into sleep, recovery, and biometric monitoring, Oura has grown from a Nordic hardware start-up into a global player in the wearable market.
For Europe’s start-up ecosystem, Oura’s planned listing carries broader significance. While its roots and design philosophy are deeply tied to Finland, the company recently transitioned to a US-based parent company, named Oura Inc., and headquartered in San Francisco. This move was aimed at accessing American venture capital while maintaining its European operations.
Its decision to prepare for a US listing rather than a European one reflects a wider pattern among high-growth European tech firms seeking deeper capital markets and greater visibility among global investors. The planned flotation arrives during renewed debate over whether Europe is losing some of its most successful technology companies to US exchanges.
Oura joins a growing list of European-founded businesses choosing Wall Street as their route to public markets, drawn by scale, liquidity, and stronger investor familiarity with consumer technology. The company’s IPO will also be seen as a test of investor sentiment towards wearable technology after a mixed few years for the sector.
Unlike smartwatches, smart rings remain a relatively young category, though interest has accelerated rapidly. Oura is widely viewed as the segment’s category leader, and its public debut could offer a clearer benchmark for how markets value next-generation health hardware combined with software subscriptions and AI services.
